From our UK edition
bluebird bio is aiming to be one of the first companies to launch a gene therapy in the UK. Often mistakenly seen as a treatment of the future, gene therapy has come of age, primed and ready to go with bluebird bio a leader in the field. Gene therapy’s arrival on the scene is very
From our UK edition
Gene therapy has been promising to transform healthcare for half a century, and still we have only around ten treatments approved for use. But that is going to change dramatically over the next five to ten years, according to Nicola Redfern, UK general manager of bluebird bio, as many treatments for rare genetic diseases are
From our UK edition
Gene therapy aims to repair, replace or add functional genes in individuals suffering from specific genetic diseases Gene therapy has traditionally been in the form of ‘gene addition’ which commonly utilises a ‘viral vector’ to introduce functional genes into the cells of eligible patients [1]. Other types of gene therapies developed more recently include the